Ono and EVQLV partner to develop new antibody drugs
Ono Pharmaceutical has signed a collaboration agreement with EVQLV to utilise its artificial intelligence (AI)-powered antibody design engine to develop…
Ono Pharmaceutical has signed a collaboration agreement with EVQLV to utilise its artificial intelligence (AI)-powered antibody design engine to develop…
Dr Reddy's Laboratories has signed a licence agreement with Coya Therapeutics to develop and commercialise the investigational combination therapy COYA…
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s supplemental biologics licence application (sBLA) for Opdivo (nivolumab)…
Eli Lilly and Company has received approval from the US Food and Drug Administration (FDA) for its non-covalent (reversible) Bruton's…
The US Food and Drug Administration (FDA) has accepted Merck (MSD)’s new supplemental biologics licence application (sBLA) for anti-PD-1 therapy…
Teva Pharmaceuticals and Sanofi have concluded a collaboration deal for co-developing and co-commercialising the anti-tumour necrosis factor-like ligand 1A (TL1A)…
Biocon subsidiary Biocon Biologics has successfully integrated Viatris' biosimilars business in 31 countries in Europe. In November 2022, Biocon Biologics…
Everest Medicines has received approval from China's National Medical Products Administration for its therapy, Nefecon, to treat primary immunoglobulin A…
Pharmaceutical company Lupin has introduced the fixed-dose triple combination (FDC) drug, Vilfuro-G, to manage chronic obstructive pulmonary disease (COPD) in…
China’s National Medical Products Administration (NMPA) has approved Shanghai Ark Biopharmaceutical’s (ArkBio) investigational new drug application for its respiratory syncytial…